Integrated therapy for HIV and tuberculosis

W Manosuthi, S Wiboonchutikul… - AIDS research and …, 2016 - Springer
Tuberculosis (TB) has been the most common opportunistic infection and cause of mortality
among HIV-infected patients, especially in resource-limited countries. Clinical …

Safety implications of combined antiretroviral and anti-tuberculosis drugs

M Cerrone, M Bracchi, S Wasserman… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Antiretroviral and anti-tuberculosis (TB) drugs are often co-administered in
people living with HIV (PLWH). Early initiation of antiretroviral therapy (ART) during TB …

Detection of tuberculosis recurrence, diagnosis and treatment response by a blood transcriptomic risk signature in HIV-infected persons on antiretroviral therapy

F Darboe, SK Mbandi, K Naidoo… - Frontiers in …, 2019 - frontiersin.org
HIV-infected individuals are at high risk of tuberculosis disease and those with prior
tuberculosis episodes are at even higher risk of disease recurrence. A non-sputum …

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a …

JK Mukonzo, A Okwera, N Nakasujja, H Luzze… - BMC infectious …, 2013 - Springer
Background HIV infection, anti-tuberculosis and efavirenz therapy are associated with
neuropsychological effects. We evaluated the influence of rifampicin cotreatment, efavirenz …

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

M Bonnet, N Bhatt, E Baudin, C Silva… - The Lancet infectious …, 2013 - thelancet.com
Background In countries with a high incidence of HIV and tuberculosis co-infection,
nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with …

Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry

MM Bastos, CCP Costa, TC Bezerra, FC da Silva… - European journal of …, 2016 - Elsevier
Acquired immunodeficiency syndrome (AIDS) is a disease caused by human
immunodeficiency virus (HIV) that affects individuals on all continents. In 1987, the …

Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings

HH Semvua, GS Kibiki, ER Kisanga… - Therapeutic drug …, 2015 - journals.lww.com
Coadministration of antituberculosis and antiretroviral therapy is often inevitable in high-
burden countries where tuberculosis (TB) is the most common opportunistic infection …

Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical …

AF Luetkemeyer, SL Rosenkranz, D Lu… - Clinical infectious …, 2013 - academic.oup.com
Abstract Background. Rifampin (RIF) upregulates CYP 450 isoenzymes, potentially lowering
efavirenz (EFV) exposure. The US EFV package insert recommends an EFV dose increase …

When to start antiretroviral therapy during tuberculosis treatment?

K Naidoo, C Baxter, SSA Karim - Current opinion in infectious …, 2013 - journals.lww.com
The trial data support the World Health Organization recommendations on when to start ART
in TB–HIV coinfected patients including earlier ART initiation in severely immune …

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype

HM McIlleron, M Schomaker, Y Ren, P Sinxadi… - Aids, 2013 - journals.lww.com
Objectives: An efavirenz-based antiretroviral therapy (ART) regimen is preferred for children
more than 3 years of age with tuberculosis. However, rifampin, a key component of …